Mutya Harsch Vyne Therapeutics Inc. (VYNE) insider trading activity

Mutya Harsch is CHIEF LEGAL OFFICER AND GC of VYNE Therapeutics Inc.. Currently has a direct ownership of 149,026 shares of VYNE, which is worth approximately $459,000. The most recent transaction as insider was on Sep 30, 2024, when has been sold 105 shares (Common Stock) at a price of $1.88 per share, resulting in proceeds of $197. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 149K

0.07% 3M change

71.11% 12M change

Total Value Held $459,000

Mutya Harsch Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Sep 30 2024	SELL Payment of exercise price or tax liability	$197 $1.88 p/Share	105 Reduced 0.07%	149,026 Common Stock
Jul 01 2024	SELL Payment of exercise price or tax liability	$274 $1.92 p/Share	143 Reduced 0.1%	149,131 Common Stock
Apr 01 2024	SELL Payment of exercise price or tax liability	$495 $3.08 p/Share	161 Reduced 0.11%	149,274 Common Stock
Jan 02 2024	SELL Payment of exercise price or tax liability	$367 $2.28 p/Share	161 Reduced 0.11%	149,435 Common Stock
Jan 01 2024	BUY Grant, award, or other acquisition	-	62,500 Added 29.47%	149,596 Common Stock
Dec 13 2023	BUY Grant, award, or other acquisition	-	62,500 Added 41.78%	87,096 Common Stock
Oct 02 2023	SELL Payment of exercise price or tax liability	$4,419 $3.83 p/Share	1,154 Reduced 4.48%	24,596 Common Stock
Jun 30 2023	SELL Payment of exercise price or tax liability	$643 $4.1 p/Share	157 Reduced 0.61%	25,750 Common Stock
May 31 2023	BUY Grant, award, or other acquisition	$12,677 $3.46 p/Share	3,664 Added 12.39%	25,907 Common Stock
Mar 31 2023	SELL Payment of exercise price or tax liability	$1,472 $3.08 p/Share	478 Reduced 2.1%	22,243 Common Stock
Mar 20 2023	BUY Open market or private purchase	$25,000 $2.5 p/Share	10,000 Added 30.56%	22,721 Common Stock
Dec 31 2022	SELL Payment of exercise price or tax liability	$271 $0.15 p/Share	1,813 Reduced 0.78%	229,144 Common Stock
Sep 30 2022	SELL Payment of exercise price or tax liability	$399 $0.22 p/Share	1,813 Reduced 0.78%	230,957 Common Stock
Jun 30 2022	SELL Payment of exercise price or tax liability	$707 $0.39 p/Share	1,813 Reduced 0.77%	232,770 Common Stock
Mar 31 2022	SELL Payment of exercise price or tax liability	$2,359 $0.65 p/Share	3,630 Reduced 1.52%	234,583 Common Stock
Mar 17 2022	BUY Grant, award, or other acquisition	-	75,000 Added 23.95%	238,213 Common Stock
Dec 31 2021	SELL Payment of exercise price or tax liability	$1,514 $1.02 p/Share	1,484 Reduced 0.9%	163,213 Common Stock
Sep 30 2021	SELL Payment of exercise price or tax liability	$2,063 $1.39 p/Share	1,484 Reduced 0.89%	164,697 Common Stock
Sep 02 2021	BUY Grant, award, or other acquisition	-	60,859 Added 26.81%	166,181 Common Stock
Jun 30 2021	SELL Payment of exercise price or tax liability	$12,464 $3.51 p/Share	3,551 Reduced 3.26%	105,322 Common Stock
Mar 31 2021	SELL Payment of exercise price or tax liability	$12,073 $6.84 p/Share	1,765 Reduced 1.6%	108,873 Common Stock
Feb 22 2021	BUY Grant, award, or other acquisition	-	29,213 Added 20.89%	110,638 Common Stock
Dec 31 2020	SELL Payment of exercise price or tax liability	$2,879 $1.58 p/Share	1,822 Reduced 0.56%	325,703 Common Stock
Nov 30 2020	BUY Grant, award, or other acquisition	$15,167 $1.45 p/Share	10,460 Added 3.09%	327,525 Common Stock
Sep 30 2020	SELL Payment of exercise price or tax liability	$3,025 $1.66 p/Share	1,822 Reduced 0.57%	317,065 Common Stock

Also insider at

STSA

Satsuma Pharmaceuticals, Inc. Healthcare

Director

Mutya Harsch

CHIEF LEGAL OFFICER AND GC

Bridgewater, NJ

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells VYNE shares.

Notify only if

Value

Insider Trading

Get notified when an Vyne Therapeutics Inc. insider buys or sells VYNE shares.

Notify only if

Operation

Value

Type

News

Receive news related to VYNE Therapeutics Inc.

Track Activities on VYNE

Account